Core Insights - Bausch Health reported revenue of $2.8 billion for the quarter ended December 2025, reflecting a year-over-year increase of 9.3% and exceeding the Zacks Consensus Estimate of $2.7 billion by 3.38% [1] - The company's EPS was $1.08, down from $1.15 in the same quarter last year, resulting in an EPS surprise of -10.5% compared to the consensus estimate of $1.21 [1] Revenue Breakdown - Total Bausch + Lomb revenues reached $1.41 billion, surpassing the average estimate of $1.37 billion by analysts, marking a year-over-year increase of 9.8% [4] - Revenues from Diversified Products were $255 million, exceeding the estimated $233.84 million, with an 11.8% increase year-over-year [4] - Bausch + Lomb's Vision Care segment generated $778 million, closely matching the average estimate of $778.13 million, reflecting a 7.6% year-over-year growth [4] - Surgical revenues amounted to $249 million, above the average estimate of $239.46 million, indicating a 7.8% increase year-over-year [4] - Total revenues excluding Bausch + Lomb were $1.39 billion, exceeding the $1.33 billion estimate, with an 8.8% year-over-year growth [4] - International revenues were reported at $306 million, surpassing the average estimate of $280.41 million, representing a 9.7% year-over-year increase [4] - Solta Medical revenues were $137 million, slightly below the average estimate of $143.46 million, showing a year-over-year decline of 0.7% [4] - Salix revenues reached $693 million, exceeding the estimated $669.92 million, with a year-over-year increase of 9.3% [4] - Bausch + Lomb Pharmaceuticals generated $378 million, surpassing the average estimate of $353.78 million, reflecting a significant year-over-year growth of 16% [4] Stock Performance - Bausch shares have returned -11.8% over the past month, compared to a -1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Blue Owl Capital Corporation reported $447.75 million in revenue for Q4 2025, a 13.5% year-over-year increase, with an EPS of $0.36 compared to $0.47 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $446.15 million by 0.36%, while the EPS surpassed the consensus estimate of $0.35 by 1.9% [1] Financial Performance Metrics - Investment income from non-controlled, non-affiliated investments showed a significant year-over-year increase of 18.6% in interest income, totaling $340.58 million, surpassing the average estimate of $334.04 million [4] - Other income from non-controlled, non-affiliated investments decreased by 16.3% year-over-year to $4.87 million, below the average estimate of $5.54 million [4] - Dividend income from controlled, affiliated investments increased by 55.8% year-over-year to $39.54 million, exceeding the average estimate of $38.3 million [4] - Total investment income from non-controlled, non-affiliated investments rose by 10.5% year-over-year to $396.25 million, surpassing the average estimate of $390.37 million [4] - Total investment income from controlled, affiliated investments increased by 50.3% year-over-year to $50.58 million, exceeding the average estimate of $48.63 million [4] Stock Performance - Over the past month, shares of Blue Owl Capital Corporation have returned -8%, compared to a -1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Kinross Gold reported a revenue of $2.02 billion for the quarter ended December 2025, marking a year-over-year increase of 42.9% and exceeding the Zacks Consensus Estimate of $1.87 billion by 7.93% [1] - The company's earnings per share (EPS) for the same period was $0.67, significantly higher than the $0.20 reported a year ago, and surpassed the consensus EPS estimate of $0.55 by 21.51% [1] Financial Performance - The production cost of sales per equivalent ounce sold was $1,297, slightly above the average estimate of $1,263 based on two analysts [4] - The total gold equivalent ounces produced were 489.67 million, exceeding the average estimate of 464.35 million from two analysts [4] - The attributable all-in sustaining cost per equivalent ounce sold was reported at $1.83 billion, compared to the average estimate of $1.79 billion from two analysts [4] Stock Performance - Kinross Gold's shares have returned -8.2% over the past month, while the Zacks S&P 500 composite experienced a -1.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

分组1 - Bausch Health reported quarterly earnings of $1.08 per share, missing the Zacks Consensus Estimate of $1.21 per share, and showing a decrease from $1.15 per share a year ago, resulting in an earnings surprise of -10.50% [1] - The company posted revenues of $2.8 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.38%, and an increase from $2.56 billion year-over-year [2] - Bausch has surpassed consensus revenue estimates three times over the last four quarters, while it has only surpassed consensus EPS estimates once in the same period [2] 分组2 - The stock has underperformed the market, losing about 13.8% since the beginning of the year, compared to the S&P 500's zero return [3] - The current consensus EPS estimate for the coming quarter is $0.82 on revenues of $2.43 billion, and for the current fiscal year, it is $4.07 on revenues of $10.49 billion [7] - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the bottom 20% of the Zacks Industry Rank, indicating potential challenges for stock performance [8]

Core Viewpoint - Ivanhoe Mines Ltd. reported quarterly earnings of $0.04 per share, matching the Zacks Consensus Estimate, but down from $0.07 per share a year ago, indicating a decrease in profitability [1] Financial Performance - The company posted revenues of $138.44 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 19.2%, compared to $40.82 million in the same quarter last year [2] - Over the last four quarters, Ivanhoe Mines has surpassed consensus EPS estimates two times and topped revenue estimates only once [2] Stock Performance - Ivanhoe Mines shares have increased approximately 3.7% since the beginning of the year, contrasting with the S&P 500's zero return [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $212.21 million, and for the current fiscal year, it is $0.44 on revenues of $855.28 million [7] - The estimate revisions trend for Ivanhoe Mines was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] Industry Context - The Mining - Miscellaneous industry, to which Ivanhoe Mines belongs, is currently in the top 22% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Core Insights - Tenaris S.A. reported revenue of $3 billion for the quarter ended December 2025, reflecting a 5.3% increase year-over-year and exceeding the Zacks Consensus Estimate of $2.92 billion by 2.46% [1] - The company's EPS was $0.87, down from $0.94 in the same quarter last year, but it surpassed the consensus estimate of $0.76 by 14.17% [1] Financial Performance - Tubes sales volume for seamless products reached 776 Kmt, exceeding the average estimate of 762.73 Kmt [4] - Total tubes sales volume was 969 Kmt, compared to the average estimate of 951.08 Kmt [4] - Welded tubes sales volume was 193 Kmt, surpassing the average estimate of 188.35 Kmt [4] - Net sales for Tubes in North America were $1.46 billion, above the average estimate of $1.39 billion, marking a year-over-year increase of 28.7% [4] - Net sales for Tubes in Asia Pacific, Middle East, and Africa were $697 million, slightly below the average estimate of $700.72 million, with a year-over-year increase of 10.8% [4] - Net sales for Tubes in Europe were $187 million, slightly above the average estimate of $184.88 million, but represented a significant year-over-year decline of 45.2% [4] - Net sales for Tubes in South America were $501 million, below the average estimate of $517.46 million, reflecting a year-over-year decrease of 15.8% [4] - Net sales for other categories reached $156 million, exceeding the average estimate of $132.18 million, with a year-over-year increase of 4% [4] - Total net sales for Tubes were $2.84 billion, slightly above the average estimate of $2.8 billion, representing a 5.3% year-over-year increase [4] Operating Income - Operating income for other segments was reported at $38 million, significantly higher than the average estimate of $18.35 million [4] - Operating income for Tubes was $516 million, exceeding the average estimate of $476.89 million [4] Stock Performance - Tenaris shares have returned 16.6% over the past month, while the Zacks S&P 500 composite has decreased by 1.3%, indicating strong relative performance [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]

Core Insights - Community Health Systems (CYH) reported a revenue of $3.11 billion for the quarter ended December 2025, reflecting a year-over-year decline of 4.9% [1] - The earnings per share (EPS) for the same period was $0, compared to -$0.42 a year ago, indicating a significant improvement [1] - The reported revenue was 1.18% below the Zacks Consensus Estimate of $3.14 billion, while the EPS exceeded the consensus estimate of -$0.32 by 100% [1] Financial Performance Metrics - Adjusted admissions were reported at 222,282, slightly below the average estimate of 222,396 from two analysts [4] - Patient days totaled 410,141, compared to the average estimate of 429,606.80 days [4] - The number of beds in service was 8,983, exceeding the average estimate of 8,679 [4] - The same-store occupancy rate was 49.6%, lower than the estimated 53.8% [4] - The total number of hospitals was 69, slightly below the average estimate of 70 [4] - Total admissions were 97,768, marginally below the average estimate of 97,799 [4] - Licensed beds were reported at 10,458, compared to the average estimate of 10,478 [4] Stock Performance - Shares of Community Health Systems have returned +9.9% over the past month, contrasting with the Zacks S&P 500 composite's -1.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Performance - For the quarter ended December 2025, Cheesecake Factory reported revenue of $961.56 million, an increase of 4.4% year-over-year [1] - EPS for the quarter was $1.00, down from $1.04 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $948.89 million, resulting in a surprise of +1.34% [1] - The company delivered an EPS surprise of +2.04%, with the consensus EPS estimate being $0.98 [1] Key Metrics - Comparable restaurant sales for The Cheesecake Factory decreased by 2.2%, compared to the average estimate of -0.9% from seven analysts [4] - Comparable restaurant sales for North Italia fell by 4%, against an average estimate of -3.2% from seven analysts [4] - The number of company-owned restaurants for The Cheesecake Factory was 218, matching the average estimate [4] - The total number of company-owned restaurants was 371, slightly below the average estimate of 372 [4] Revenue Breakdown - Revenues for North Italia were reported at $88.17 million, below the average estimate of $90.2 million, but represented an 8.4% year-over-year increase [4] - Revenues for The Cheesecake Factory restaurants were $681.43 million, exceeding the average estimate of $669.8 million, with a year-over-year change of +1.8% [4] - Revenues for Other segments were $92.51 million, slightly below the average estimate of $93.47 million, reflecting an 8.6% year-over-year increase [4] - Revenues for Other FRC were $99.44 million, surpassing the average estimate of $95.67 million, with a significant year-over-year change of +16.8% [4] Stock Performance - Shares of Cheesecake Factory have returned +8.5% over the past month, while the Zacks S&P 500 composite experienced a -1.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - CF Industries reported a revenue of $1.87 billion for the quarter ended December 2025, marking a 22.8% increase year-over-year, with an EPS of $2.99 compared to $1.89 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $1.79 billion by 4.69%, and the EPS surpassed the consensus estimate of $2.50 by 19.79% [1] Financial Performance - CF Industries' shares returned +6.1% over the past month, while the Zacks S&P 500 composite declined by -1.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3] Sales Volume and Pricing - Ammonia sales volume reached 1,272 KTon, exceeding the average estimate of 1,164.55 KTon [4] - Total product sold was 4,528 KTon, slightly below the average estimate of 4,721.13 KTon [4] - Granular Urea sales volume was 857 KTon, below the estimated 1,021.51 KTon [4] - UAN sales volume was 1,606 KTon, compared to the average estimate of 1,693.76 KTon [4] - Average selling price for Granular Urea was $434.00, above the estimate of $412.49 [4] - Average selling price for Ammonia was $557.00, exceeding the estimate of $485.54 [4] Net Sales Performance - Net Sales for Ammonia were $708 million, surpassing the estimate of $570.71 million, reflecting a year-over-year increase of 23.8% [4] - Net Sales for Granular Urea were $372 million, below the estimate of $423.03 million, with a year-over-year change of +6.9% [4] - Net Sales for UAN were $564 million, slightly above the estimate of $560.37 million, representing a significant year-over-year increase of 51.6% [4] - Net Sales for AN were $81 million, exceeding the estimate of $71.74 million, but showing a year-over-year decline of 19.8% [4] - Net Sales for Other products were $147 million, compared to the estimate of $153.66 million, with a year-over-year change of +12.2% [4]

Reliance (RS) reported $3.5 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 11.9%. EPS of $2.40 for the same period compares to $2.22 a year ago.The reported revenue represents a surprise of +3.44% over the Zacks Consensus Estimate of $3.38 billion. With the consensus EPS estimate being $2.80, the EPS surprise was -14.36%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ex ...